Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer

Journal of Sexual Medicine

Volumn 7, Issue 3, 2010, Pages 1062-1073

  Prasad, Michaella M ^a   Prasad, Sandip M ^a   Hevelone, Nathanael D ^a   Gu, Xiangmei ^a   Weinberg, Aaron C ^a   Lipsitz, Stuart R ^a   Palapattu, Ganesh S ^b   Hu, Jim C ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Erectile dysfunction; PDE5 inhibitors; Pharmacotherapy; Prostate cancer

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1;

AGE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; COMORBIDITY; DATA ANALYSIS; DRUG USE; ERECTILE DYSFUNCTION; HUMAN; INTRACAVERNOUS DRUG ADMINISTRATION; MINIMALLY INVASIVE PROCEDURE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; REVIEW; SUPPOSITORY;

EID: 77950834674     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01644.x     Document Type: Review

References (41)

1. Siglin J, Kubicek GJ, Leiby B, Valicenti RK. Time of decline in sexual function after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 76:31-5.
2. Stanford JL, Feng Z, Hamilton AS, Gililand FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 2000, 283:354-60.
3. Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard SJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW. Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study. J Clin Oncol 1998, 16:275-83.
4. Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: A meta-analysis. J Sex Med 2009, 6:2538-46.
5. Fransson P, Lund J-A, Damber J-E, Klepp O, Wiklund F, Fossa S, Widmark A. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol 2009, 10:370-80.
6. Kendirci M, Bejma J, Hellstrom WJ. Update on erectile dysfunction in prostate cancer patients. Curr Opin Urol 2006, 16:186-95.
7. Briganti A, Capitanio U, Chun FK, Karakiewicz PI, Salonia A, Bianchi M, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Prediction of sexual function after radical prostatectomy. Cancer 2009, 115:3150-9.
8. Bergman J, Gore JL, Penson DF, Kwan L, Litwin MS. Erectile aid use by men treated for localized prostate cancer. J Urol 2009, 182:649-54.
9. Stephenson R, Mori M, Hsieh Y, Beer T, Stanford J, Gilliland F, Hoffman R, Potosky A. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: Patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. J Urol 2005, 174:646-50. discussion 50
10. Giuliano F, Amar E, Chevallier D, Montaigne O, Joubert JM, Chartier-Kastler E. How urologists manage erectile dysfunction after radical prostatectomy: A national survey (REPAIR) by the French urological association. J Sex Med 2008, 5:448-57.
11. Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol 2004, 45:123-33.
12. Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, Stief C. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008, 54:924-31.
13. Montorsi F, Nathan H, McCullough A, Brock G, Broderick G, Ahuka S, Whitaker S, Hoover A, Novack D, Murphy A. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: A randomized, double-blind, placebo controlled trial. J Urol 2004, 172:1036-41.
14. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-61.
15. Candy B, Jones L, Williams R, Tookman A, King M. Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: Findings from a Cochrane systematic review. BJU Int 2008, 102:426-31.
16. McCullough AR, Levine LA, Padma-Nathan H. Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: Subanalysis of a longitudinal randomized double-blind placebo-controlled trial. J Sex Med 2008, 5:476-84.
17. Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siefel R, Montorsi F, Guiliano F, Brock G. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008, 20:479-86.
18. Sun P, Seftel A, Swindle R, Ye W, Pohl G. The costs of caring for erectile dysfunction in a managed care setting: Evidence from a large national claims database. J Urol 2005, 174:1948-52.
19. Adamson DM, Chang S, Hansen LG. Health research data for the real world: The Marketscan Databases 2006, Ann Arbor, MI, Thomson Medstat
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987, 40:373-83.
21. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations. Prostate 1983, 4:473-85.
22. Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus S, Liebert M, Moul JW, Tangen C, Thrasher JB, Thompson I. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 2007, 178:597-601.
23. Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, Rigatti P, Pizzini G, Miani A. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial. J Urol 1997, 158:1408-10.
24. Gontero P, Fontana F, Bagnasacco A, Panella M, Kocjancic E, Pretti G, Frea B. Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol 2003, 169:2166-9.
25. Gellad ZF, Lyles KW. Direct-to-consumer advertising of pharmaceuticals. Am J Med 2007, 120:475-80.
26. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med 2002, 346:498-505.
27. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 2007, 357:673-81.
28. Black PC, Penson DF. Prostate cancer on the Internet-information or misinformation? J Urol 2006, 175:1836-42. discussion 42
29. Briganti A, Gallina A, Salonia A, Zanni G, Cestari A, Guazzoni G, Rigatti P, Montorsi F. The case for postoperative PDE-5 inhibitor drug treatment after radical prostatectomy. J Endourol 2008, 22:2025-7. discussion 35
30. Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Can phosphodiesterase type 5 inhibitors cure erectile dysfunction? Eur Urol 2006, 49:979-86.
31. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med 2009, 6:1794-808. quiz 93, 809-10
32. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: Updates on optimal utilization for sexual concerns and rare toxicities in this class. J Sex Med 2009, 6:2352-64. quiz 65-6
33. Salonia A, Gallina A, Zanni G, Briganti A, Dehò F, Saccà A, Suardi N, Barbieri L, Guazzoni G, Rigatti P, Montorsi F. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008, 53:564-70.
34. Montorsi F, McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: A systematic review of clinical data. J Sex Med 2005, 2:658-67.
35. Teloken PE, Parker M, Mohideen N, Mulhall JP. Predictors of response to sildenafil citrate following radiation therapy for prostate cancer. J Sex Med 2009, 6:1135-40.
36. Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007, 109:2239-47.
37. Schroeck FR, Krupski TL, Sun L, Albala DM, Price MM, Polascik TJ, Robertson CN, Tewari AK, Moul JW. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol 2008, 54:785-93.
38. Khera M. Androgens and erectile function: A case for early androgen use in postprostatectomy hypogonadal men. J Sex Med 2009, 6(3):234-8. Suppl
39. Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, Lipshultz LI. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009, 6:1165-70.
40. Salonia A, Zanni G, Gallina A, Saccà A, Sangalli M, Naspro R, Briganti A, Farina E, Roscigno M, Dapozzo LF, Rigatti P, Montorsi F. Baseline potency in candidates for bilateral nerve-sparing radical retropubic prostatectomy. Eur Urol 2006, 50:360-5.
41. Salomon G, Isbarn H, Budaeus L, Schlomm T, Briganti A, Steuber T, Heinzer H, Haese A, Graefen M, Karakiewicz PI, Huland H, Chun F. Importance of baseline potency rate assessment of men diagnosed with clinically localized prostate cancer prior to radical prostatectomy. J Sex Med 2009, 6:498-504.